Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections
Top Cited Papers
Open Access
- 1 April 2015
- journal article
- review article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 2 (2), ofv050
- https://doi.org/10.1093/ofid/ofv050
Abstract
Antimicrobial resistance in Gram-negative bacteria is an emerging and serious global public health threat. Carbapenems have been used as the “last-line” treatment for infections caused by resistant enterobacteriaceae, including those producing extended spectrum ß-lactamases. However, enterobacteriaceae that produce carbapenemases, which are enzymes that deactivate carbapenems and most other ß-lactam antibiotics, have emerged and are increasingly being reported worldwide. Despite this increasing burden, the most optimal treatment for carbapenem-resistant enterobacteriaceae (CRE) infections is largely unknown. For the few remaining available treatment options, there is limited efficacy data to support their role in therapy. Nevertheless, current treatment options include the use of older agents, such as polymyxins, fosfomycin, and aminoglycosides, which have been rarely used due to efficacy and/or toxicity concerns. Optimization of dosing regimens and combination therapy are additional treatment strategies being explored. CRE infections are associated with poor outcomes and high mortality. Continued research is critically needed to determine the most appropriate treatment.Keywords
This publication has 85 references indexed in Scilit:
- High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteriaCritical Care, 2014
- Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challengeClinical Microbiology & Infection, 2013
- OXA-48-like carbapenemases: the phantom menaceJournal of Antimicrobial Chemotherapy, 2012
- Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of PatientsAntimicrobial Agents and Chemotherapy, 2011
- Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolatesJournal of Antimicrobial Chemotherapy, 2010
- In VivoEfficacy of Simulated Human Dosing Regimens of Prolonged-Infusion Doripenem against Carbapenemase- ProducingKlebsiella pneumoniaeAntimicrobial Agents and Chemotherapy, 2010
- Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomesDiagnostic Microbiology and Infectious Disease, 2010
- Elucidation of the Pharmacokinetic/Pharmacodynamic Determinant of Colistin Activity against Pseudomonas aeruginosa in Murine Thigh and Lung Infection ModelsAntimicrobial Agents and Chemotherapy, 2010
- Regional Dissemination of KPC-Producing Klebsiella pneumoniaeAntimicrobial Agents and Chemotherapy, 2009
- Pharmacokinetic Considerations regarding Tigecycline for Multidrug-Resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii UrosepsisJournal of Clinical Microbiology, 2009